Evidence map›Paper›PMID 34998954›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2022

miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma.

Holly Holliday, Jessica Yang, Eoin Dodson, Iva Nikolic, Alvin Kamili, Madeleine Wheatley, Niantao Deng, Sarah Alexandrou, Thomas P Davis, Maria Kavallaris and 8 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 2 countries.

Holly HollidayGarvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2010, Australia; Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2031, Australia; School of Women's and Children's Health, UNSW Sydney, Sydney, NSW 2052, Australia.
Jessica YangGarvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Eoin DodsonGarvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia.
Iva NikolicVictorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, VIC 3002, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3002, Australia.
Alvin KamiliChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2031, Australia; School of Women's and Children's Health, UNSW Sydney, Sydney, NSW 2052, Australia.
Madeleine WheatleyChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2031, Australia.
Niantao DengGarvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2010, Australia.
Sarah AlexandrouGarvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2010, Australia.
Thomas P DavisARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Australian Institute for Bioengineering, The University of Queensland, Brisbane, QLD 2072, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science & Technology, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, VIC 3052, Australia.
Maria KavallarisChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2031, Australia; School of Women's and Children's Health, UNSW Sydney, Sydney, NSW 2052, Australia; Australian Centre for Nanomedicine, UNSW Sydney, Sydney, NSW 2052, Australia.
C Elizabeth CaldonGarvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2010, Australia.
Joshua McCarrollChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2031, Australia; School of Women's and Children's Health, UNSW Sydney, Sydney, NSW 2052, Australia; Australian Centre for Nanomedicine, UNSW Sydney, Sydney, NSW 2052, Australia.
Katleen De PreterCancer Research Institute Ghent, Ghent University, Ghent B-9000, Belgium.
Pieter MestdaghCancer Research Institute Ghent, Ghent University, Ghent B-9000, Belgium.
Glenn M MarshallChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2031, Australia; Kids Cancer Centre, Sydney Children's Hospital, Sydney, NSW 2031, Australia.
Kaylene J SimpsonVictorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, VIC 3002, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC 3002, Australia.
Jamie FletcherChildren's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, NSW 2031, Australia; School of Women's and Children's Health, UNSW Sydney, Sydney, NSW 2052, Australia.
Alexander SwarbrickGarvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; St Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Sydney, NSW 2010, Australia. Electronic address: a.swarbrick@garvan.org.au.
UNSW Sydney · AUGarvan Institute of Medical Research · AUCancer Research Institute Ghent · BEUniversity of Melbourne · AUCancer Institute of New South Wales · AUSt Vincent's Clinic · AUSydney Children's Hospital · AUUniversity of Queensland · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuroblastoma is a deadly childhood cancer arising in the developing sympathetic nervous system. High-risk patients are currently treated with intensive chemotherapy, which is curative in only 50% of children and leaves some surviving patients with life-long side effects. microRNAs (miRNAs) are critical regulators of neural crest development and are deregulated during neuroblastoma tumorigenesis, making miRNA-based drugs an attractive therapeutic avenue. A functional screen of >1,200 miRNA mimics was conducted in neuroblastoma cell lines to discover miRNAs that sensitized cells to low doses (30% inhibitory concentration [IC

Indexed as

MicroRNAsNeuroblastomaChildDoxorubicinGene Expression Regulation, NeoplasticHumansDoxorubicinMicroRNAsMIRN380 microRNA, humanMIRN485 microRNA, humanchemotherapydoxorubicinhigh-throughput screenmiR-380-3pmiR-485-3pmiR-99b-5pmiRNAmiRNA-based therapynanoparticleneuroblastoma

Identifiers

PMID34998954
PMCPMC8899605
OpenAlexW4206520253

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.